Comparing the Use of Dienogest and Combined Oral Contraceptive Pills (Microgynon) to Reduce the Risk of Recurrence of Endometriotic Cyst After Conservative Surgery
NCT ID: NCT02385448
Last Updated: 2015-04-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
144 participants
INTERVENTIONAL
2015-02-28
2019-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trial Comparing Preoperative Dienogest Therapy Followed by Surgery vs. Upfront Surgery to Save Ovarian Reserve in Young Women With Ovarian Endometrioma
NCT02728245
Desogestrel for the Preoperative Treatment of Endometrioma Compared With Placebo
NCT04941833
Postoperative Cyclic Oral Contraceptive Use for the Prevention of Endometrioma Recurrence
NCT01092494
Effects of Dienogest and Dienogest Plus Estradiol Valerate in Ovarian Endometrioma
NCT03789123
Postoperative Desogestrel for Endometriosis Related Pain
NCT01559480
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dienogest
Dienogest
The dienogest group will receive dienogest 2mg daily for 24 months postoperatively
Combined oral contraceptive pills
Microgynon
The combined oral contraceptive pills group will be given cyclical Microgynon for 24 months.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dienogest
The dienogest group will receive dienogest 2mg daily for 24 months postoperatively
Microgynon
The combined oral contraceptive pills group will be given cyclical Microgynon for 24 months.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Older than the age of legal consent (i.e. 18 years old)
* Sonographic diagnosis of ovarian endometrioma with diameter at least 4cm on 2 separate scans at least 6 weeks apart
* No contraindication to use of progesterone or combined oral contraceptive pills
* Not attempting to conceive either at the time of study entry or for at least 2 years after surgery
* Willing and able to participate after the study has been explained
Exclusion Criteria
* Contraindications to progestogens or oral contraceptive pills
* Unwillingness to tolerate menstrual irregularity
* Planning pregnancy within 2 years of study
* Cannot understand English, Cantonese or Putonghua
18 Years
51 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The University of Hong Kong
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jennifer K.Y. Ko, MBBS, MRCOG
Role: PRINCIPAL_INVESTIGATOR
The University of Hong Kong, Queen Mary Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Queen Mary Hospital
Hong Kong, , Hong Kong
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UW 14-097
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.